Skip to main content

Advertisement

SpringerLink
Log in

Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Advancements in the diagnosis and treatment of prostate cancer (PC) have rapidly progressed through the past years. Various factors should be taken into account while treating individual patients to ensure optimal and careful decision making. The purpose of this consensus review is to summarize the current practice patterns when managing patients with advanced prostate cancer (APC) as there is still a lack of or very limited evidence on its clinical management in some areas.

Methods

Pre-defined questions were shared with experts prior to the consensus session that took place in Cairo, Egypt in April 2019 during the 8th International gastrointestinal, liver and uro-oncology conference (IGILUC). Voting was based mainly on the expert opinions of the panel after a thorough discussion and review of available evidence from guidelines or best evidence available concerning the topic at hand.

Results

A strong consensus or unanimity was reached on 47% of the proposed questions. Notably, the panelists reached consensus on several topics based on high-level expert opinion. These findings contribute in several ways to our understanding of the management of PC and provide a basis for future recommendations. There was also a lack of consensus on other several topics, which suggests the need for further supporting data addressing these knowledge gaps.

Conclusion

This review offers a thorough understanding of APC practice and offers insight on the various opinions shared amongst experts in the field that can serve as guidance regionally and deepens our understanding of disease management globally.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

    Article  Google Scholar 

  2. Collaboration GB of DC (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study Global Burden. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688

    Article  Google Scholar 

  3. Thompson IMJ, Tangen CM, Paradelo J et al (2006) Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296:2329–2335. https://doi.org/10.1001/jama.296.19.2329

    Article  CAS  PubMed  Google Scholar 

  4. Bolla M, van Poppel H, Tombal B et al (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England) 380:2018–2027. https://doi.org/10.1016/S0140-6736(12)61253-7

    Article  Google Scholar 

  5. Wiegel T, Bottke D, Steiner U et al (2009) Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27:2924–2930. https://doi.org/10.1200/JCO.2008.18.9563

    Article  PubMed  Google Scholar 

  6. Gillessen S, Attard G, Beer TM et al (2018) Management of patients with advanced prostate cancer: the Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 73:178–211. https://doi.org/10.1016/j.eururo.2017.06.002

    Article  PubMed  Google Scholar 

  7. Parker C, Clarke NW, Cook A, Kynaston HG, Meidahl Petersen P et al (2019) Timing of radiotherapy (RT) after radical prostatectomy (RP): first results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047]. Ann Oncol 30(suppl_5):v851–v934. https://doi.org/10.1093/annonc/mdz394

    Article  Google Scholar 

  8. Touijer KA, Mazzola CR, Sjoberg DD et al (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20–25. https://doi.org/10.1016/j.eururo.2013.03.053

    Article  PubMed  Google Scholar 

  9. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al (2019) EAU guidelines: EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. EAU Guidelines Office, Arnhem

    Google Scholar 

  10. James ND, de Bono JS, Spears MR et al (2017) Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377:338–351. https://doi.org/10.1056/NEJMoa1702900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mohler JL, Antonarakis ES, Armstrong AJ et al (2019) Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 17:479–505. https://doi.org/10.6004/jnccn.2019.0023

    Article  CAS  PubMed  Google Scholar 

  12. Li R, Ravizzini GC, Gorin MA et al (2018) The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis 21:4–21. https://doi.org/10.1038/s41391-017-0007-8

    Article  PubMed  Google Scholar 

  13. Schuster DM, Nanni C, Fanti S et al (2014) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med 55:1986–1992. https://doi.org/10.2967/jnumed.114.143628

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Perera M, Papa N, Christidis D et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937. https://doi.org/10.1016/j.eururo.2016.06.021

    Article  PubMed  Google Scholar 

  15. Vag T, Heck MM, Beer AJ et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24:1821–1826. https://doi.org/10.1007/s00330-014-3240-8

    Article  PubMed  Google Scholar 

  16. Nanni C, Schiavina R, Rubello D et al (2013) The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? Nucl Med Commun 34:831–833

    Article  Google Scholar 

  17. Lehmann J, Flesch M, Gedamke M (2019) Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone-sensitive prostate cancer (hsPCa). J Clin Oncol 37:153. https://doi.org/10.1200/JCO.2019.37.7_suppl.153

    Article  Google Scholar 

  18. Martín-Merino E, Johansson S, Morris T, Rodríguez LAG (2011) Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer. Drug Saf 34:1061–1077. https://doi.org/10.2165/11594540-000000000-00000

    Article  PubMed  Google Scholar 

  19. Albertsen PC, Klotz L, Tombal B et al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565–573. https://doi.org/10.1016/j.eururo.2013.10.032

    Article  CAS  PubMed  Google Scholar 

  20. Rick FG, Block NL, Schally AV (2013) An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 6:391–402. https://doi.org/10.2147/OTT.S32426

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–629. https://doi.org/10.1016/j.eururo.2016.08.003

    Article  PubMed  Google Scholar 

  22. Klotz L, Boccon-Gibod L, Shore ND et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531–1538. https://doi.org/10.1111/j.1464-410X.2008.08183.x

    Article  CAS  PubMed  Google Scholar 

  23. Shore ND (2013) Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol 5:11–24. https://doi.org/10.1177/1756287212461048

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Sweeney CJ, Chen Y-H, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746. https://doi.org/10.1056/NEJMoa1503747

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158. https://doi.org/10.1016/S1470-2045(12)70560-0

    Article  CAS  PubMed  Google Scholar 

  26. Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381:13–24. https://doi.org/10.1056/NEJMoa1903307

    Article  CAS  PubMed  Google Scholar 

  27. Clarke NW, Ali A, Ingleby FC et al (2019) Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol Off J Eur Soc Med Oncol. https://doi.org/10.1093/annonc/mdz396

    Article  Google Scholar 

  28. Davis ID, Martin AJ, Stockler MR et al (2019) Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 381:121–131. https://doi.org/10.1056/NEJMoa1903835

    Article  CAS  PubMed  Google Scholar 

  29. Hoyle AP, Ali A, James ND et al (2019) Abiraterone in “High-” and “Low-risk” metastatic hormone-sensitive prostate cancer. Eur Urol. https://doi.org/10.1016/j.eururo.2019.08.006

    Article  PubMed  Google Scholar 

  30. Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) 392:2353–2366. https://doi.org/10.1016/S0140-6736(18)32486-3

    Article  Google Scholar 

  31. Boeve LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a Prospective Randomised Clinical Trial. Eur Urol 75:410–418. https://doi.org/10.1016/j.eururo.2018.09.008

    Article  PubMed  Google Scholar 

  32. Fischer S, Gillessen S, Sydes MR, Omlin AG (2018) Differences in treatment recommendations for advanced prostate cancer according to region and medical specialization: analysis of the APCCC 2017 voting results. Ann Oncol 29(suppl_8):viii271-viii302. https://doi.org/10.1093/annonc/mdy284

  33. Scher HI, Graf RP, Schreiber NA et al (2018) Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer assessment of validity of AR-V7 in tumor cells as a predictive biomarker for Ca. JAMA Oncol 4:1179–1186. https://doi.org/10.1001/jamaoncol.2018.1621

    Article  PubMed  PubMed Central  Google Scholar 

  34. Antonarakis ES, Lu C, Wang H et al (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:1028–1038. https://doi.org/10.1056/NEJMoa1315815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245. https://doi.org/10.1200/JCO.2007.12.4008

    Article  CAS  PubMed  Google Scholar 

  36. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England) 376:1147–1154. https://doi.org/10.1016/S0140-6736(10)61389-X

    Article  CAS  Google Scholar 

  37. Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377:352–360. https://doi.org/10.1056/NEJMoa1704174

    Article  CAS  PubMed  Google Scholar 

  38. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. https://doi.org/10.1056/NEJMoa1405095

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Karantanos T, Karanika S, Gignac G (2016) Uncontrolled diabetes predicts poor response to novel antiandrogens. Endocr Relat Cancer 23:691–698. https://doi.org/10.1530/ERC-16-0222

    Article  CAS  PubMed  Google Scholar 

  40. Szmulewitz RZ, Peer CJ, Ibraheem A et al (2018) Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer. J Clin Oncol 36:1389–1395. https://doi.org/10.1200/JCO.2017.76.4381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful for all the panel members and moderators of this meeting for their scientific contribution.

Author information

Authors and Affiliations

  1. Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    Hesham Elghazaly, Khalid Abdelkarim, Lobna Ezz El-Arab, Hesham Elwakil & Mai Ezz El Din

  2. Department of Urology, University Hospital Nord St. Etienne, St. Etienne, France

    Nicolas Mottet

  3. Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

    Jorge Garcia

  4. Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France

    Stephane Oudard

  5. Department of Radiation Oncology, University of California, San Francisco, CA, USA

    Mack Roach

  6. Department of Urology, Hôpital Henri Mondor, Creteil, France

    Claude Abbou

  7. Department of Urology and Urologic Oncology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

    Axel Merseburger

  8. Department of Urology, Hampshire Hospitals, NHS Foundation Trust, Basingstoke, UK

    Amr Emara

  9. Clinical Oncology Department, Assiut University Cancer Centre, Assiut, Egypt

    Samir Shehata

  10. Clinical Oncology Department, Tanta University, Tanta, Egypt

    Hesham Tawfik

  11. Medical Oncology Department National Cancer Institute, Cairo University, Cairo, Egypt

    Ola Khorshid

  12. Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

    Ahmed Selim

  13. Urology Department, Alexandria University, Alexandria, Egypt

    Akram Assem

  14. Medical Oncology Department, King Faisal Specialist Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia

    Shouki Bazarbashi

  15. Department of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

    Abbass Omar

  16. Department of Clinical Oncology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Mohamed Elashry

  17. Department of Clinical Oncology, Faculty of Medicine, Menoufia University, Al Minufya, Egypt

    Mohamed Abou ElFotouh

  18. Department of Urology, Ain Shams University, Cairo, Egypt

    Tarek Osman

Authors
  1. Hesham Elghazaly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Mottet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jorge Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephane Oudard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mack Roach
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claude Abbou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Axel Merseburger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Amr Emara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Samir Shehata
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hesham Tawfik
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ola Khorshid
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ahmed Selim
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Akram Assem
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Khalid Abdelkarim
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lobna Ezz El-Arab
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Shouki Bazarbashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Abbass Omar
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Hesham Elwakil
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Mohamed Elashry
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mohamed Abou ElFotouh
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Tarek Osman
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Mai Ezz El Din
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HE: Project development and manuscript editing. NM: Manuscript editing. AM: Manuscript editing. TO: Project development. MEED: Project development and manuscript editing.

Corresponding author

Correspondence to Hesham Elghazaly.

Ethics declarations

Involvement of human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elghazaly, H., Mottet, N., Garcia, J. et al. Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts. World J Urol 39, 1421–1429 (2021). https://doi.org/10.1007/s00345-020-03328-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-020-03328-3

Keywords

Search

Navigation